Oxford Immunotec entered MOU with Green Cross to market T-SPOT Discovery SARS-CoV-2 Kit in South Korea
On Feb. 8, 2021, Oxford Immunotec announced it had entered into an MOU with Green Cross Medical to…
On Feb. 8, 2021, Oxford Immunotec announced it had entered into an MOU with Green Cross Medical to…
On Feb. 8, 2021, the NIH announced that an international randomized, controlled Phase 3 clinical trial had begun…
On Feb. 8, 2021, Eiger BioPharmaceuticals announced that the final results from the Phase 2 ILIAD (Interferon Lambda…
On Feb. 8, 2021, NanoViricides announced that its broad-spectrum anti-coronavirus drug candidate for the treatment of COVID-19 infections…
On Feb. 8, 2021, Repligen and Navigo Proteins announced that they had completed the development and initiated the…
On Feb. 8, 2021, a machine-learning algorithm developed at UT Southwestern estimated that the number of COVID-19 cases…
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
On Feb. 5, 2021, CureVac announced that it had entered a collaboration with the UK Government to develop…
On Feb. 5, 2021, the Wellcome Sanger Institute announced that to date it had sequenced 136,383 coronavirus genomes….
On Feb. 5, 2021, the FDA approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients…
On Feb. 5, 2021, Oxford University announced that a preprint of ongoing work to assess effectiveness of Oxfordメs…
On Feb. 4, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
On Feb. 4, 2021, the U.S. Department of Defense Secretary of Defense directed all individuals on military installations…
On Feb. 4, 2021, Johnson & Johnson announced that subsidiary Janssen Biotech, had submitted an application to the…
On Feb. 3, 2021, COVAX notified countries in Africa of the estimated dose allocation for the first phase…
On Feb. 3, 2021, XPhyto announced an agreement with Applied Pharmaceutical Innovation for the synthesis of pharmaceutical grade…
On Feb. 3, 2021, Vaxart announced preliminary data from its Phase 1 study of VXA-CoV2-1 showing that its…
On Feb. 3, 2021, Dynavax Technologies and Serum Institute of India announced that the first participant has been…
On Feb. 3, 2021, Avid Bioservices and Humanigen announced that they had entered into a manufacturing services agreement…
On Feb. 3, 2021, BD (Becton, Dickinson) announced the CE mark of BD Multitestル 6-Color TBNK Reagent with…
On Feb. 3, 2021, Bristol-Myers and The Rockefeller University announced an agreement under which Bristol Myers Squibb was…
On Feb. 2, 2021, GlaxoSmithKline and CureVac announced a new タ150m collaboration, building on their existing relationship, to…
On Feb. 2, 2021, Oragenics announced that the stabilized pre-fusion spike protein CoV-2 S-2P created by the National…
On Feb. 2, 2021, VBI Vaccines announced that the FDA had accepted its filing of the Biologics License…
On Feb. 1, 2021, Roche announced it had obtained the CE mark for its new SARS-CoV-2 Rapid Antigen…
On Feb. 1, 2021, researchers at the National Institutes of Health and their collaborators found that inhaling unfragmented…
On Feb. 1, 2021, Clover Biopharmaceuticals and Dynavax Technologies announced a plan to initiate a global Phase 2/3…
On Feb. 1, 2021, Dynavax Technologies and the Coalition for Epidemic Preparedness Innovations (CEPI) announced they have entered…
On Feb. 1, 2021, Dynavax Technologies announced Valneva had informed it that the UK Government exercised its option…
On Feb. 1, 2021, Pfizer and BioNTech announced that preclinical data in non-human primate and mouse models from…